9 completed, 2 terminated, 1 recruiting, 1 unknown. 13 Phase 1, 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 13 | Completed 9, Terminated 2, Recruiting 1, Unknown 1 |
| Phase 2 | 5 | Completed 2, Recruiting 1, Terminated 1, Unknown 1 |
Follow Matched placebo: new trials by email Literature Review of Matched placebo trials Research Report on Matched placebo
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| To studyJUV-161 Administered to Healthy Volunteers Undergoing Unilateral Lower Limb Immobilization (ULLI) JUV-161, Placebo - Healthy Volunteers | Phase 1 / Phase 2 | Recruiting | Juvena Therapeutics | 36 | 2026-02-28 | 2026-04-20 |
| Study Investigating the Safety, Tolerability, and PK, PD, of CB-0406 CB-0406 100 mg, CB-0406 200 mg, CB-0406 400 mg - Healthy Volunteers | Phase 1 | Completed | Gilead Sciences | 90 | 2020-07-07 | 2021-06-11 |
| To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants BMS-986177, Matched Placebo - Thrombosis | Phase 1 | Completed | Bristol-Myers Squibb | 33 | 2017-06-28 | 2018-06-01 |
| A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis IVA, TEZ/IVA, VX-445 - Cystic Fibrosis | Phase 1 / Phase 2 | Completed | Vertex Pharmaceuticals Incorporated | 225 | 2017-01-23 | 2022-01-18 |
| A Phase I, Randomized, Placebo-controlled, Double Blind, Repeat Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Gastrointestinal Transit Time and Pharmacodynamic Biomarkers of GSK3179106 in Normal Subjects GSK3179106, Matched Placebo - Irritable Bowel Syndrome | Phase 1 | Completed | GlaxoSmithKline | 46 | 2016-06-01 | 2017-01-18 |
| Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects nangibotide, Placebo - Healthy Subjects | Phase 1 | Completed | Inotrem | 27 | 2016-04-01 | 2025-02-10 |
| The Effect of Melatonin Upon Post-Acute Withdrawal Among Males in a Residential Treatment Program Melatonin, Matched Placebo - Substance Withdrawal Syndrome | Phase 1 / Phase 2 | Completed | Duquesne University | 70 | 2015-05-01 | 2016-08-08 |
| A Phase 1, 2-Part Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Multiple Doses of ASLAN003 in Healthy Elderly Subjects ASLAN003, Matched Placebo - Healthy Elderly Subjects (Age ≥55 Years) | Phase 1 | Completed | ASLAN Pharmaceuticals | 7 | 2014-10-01 | 2016-11-02 |
| Development of Ibudilast for Alcohol Use Disorder Ibudilast, Matched placebo - Alcohol Use Disorders | Phase 1 | Completed | University of California, Los Angeles | 24 | 2013-12-01 | 2016-02-23 |
| Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER) Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs), matched placebo - Idiopathic Pulmonary Fibrosis (IPF) | Phase 1 | Terminated | Joshua M Hare | 9 | 2013-11-13 | 2021-03-09 |
| Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures dapivirine, matched placebo, universal placebo - Topical Penile Exposures | Phase 1 | Completed | International Partnership for Microbicides, Inc. | 48 | 2011-03-01 | 2017-09-08 |
| Safety and Activity of ORE1001 in Subjects With Ulcerative Colitis ORE1001, Placebo - Mild to Moderate Ulcerative Colitis | Phase 1 / Phase 2 | Unknown | Ore Pharmaceuticals, Inc. | 50 | 2009-12-01 | 2011-06-08 |
| Ginkgo Biloba to Improve Short-Term Memory Losses Associated With Electroconvulsive Therapy (ECT) ginkgo biloba, matched placebo - Memory, Short-Term | Phase 1 / Phase 2 | Terminated | Medical University of South Carolina | 50 | 2003-02-01 | 2018-07-18 |
Alcoholism (1) · Anxiety Disorders (1) · Colitis, Ulcerative (1) · Cystic Fibrosis (1) · Depression (1) · Idiopathic Pulmonary Fibrosis (1) · Irritable Bowel Syndrome (1) · Pulmonary Fibrosis (1) · Sleep Initiation and Maintenance Disorders (1) · Substance Withdrawal Syndrome (1) · Thrombosis (1)
ASLAN Pharmaceuticals (1) · Bristol-Myers Squibb (1) · Duquesne University (1) · Gilead Sciences (1) · GlaxoSmithKline (1) · Inotrem (1) · International Partnership for Microbicides, Inc. (1) · Joshua M Hare (1) · Juvena Therapeutics (1) · Medical University of South Carolina (1) · Ore Pharmaceuticals, Inc. (1) · University of California, Los Angeles (1) · Vertex Pharmaceuticals Incorporated (1)
United States (7) · Australia (3) · Belgium (1) · Canada (1) · India (1) · Netherlands (1) · New Zealand (1) · Singapore (1) · United Kingdom (1)
Charles H. Kellner, M.D. (1) · Chris Brett, MD (1) · Elaine Watkins, DO, MSPH (1) · John S. Markowitz, PharmD (1) · Lara Ray, PhD (1) · Marilyn K. Glassberg, MD (1) · Ross D. Cranston, MD, FRCP (1) · Thomas W Uhde, MD (1) · Vincent Giannetti, Ph.D. (1)
PMID 24070431, PMID 29794557, PMID 29885068, PMID 30277655, PMID 30334692, PMID 33331662, PMID 36102596, PMID 37983082
2017 (1), R21AA022214 (1), R21AT000939 (1)